help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cremonini, N.
Right arrow Articles by Zampa, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cremonini, N.
Right arrow Articles by Zampa, G. A.

Journal of Clinical Endocrinology & Metabolism, Vol 75, 1166-1169, Copyright © 1992 by Endocrine Society

ARTICLES

Atypical McCune-Albright syndrome associated with growth hormone- prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results

N Cremonini, E Graziano, V Chiarini, A Sforza and GA Zampa
Endocrine and Metabolic Diseases Division, Maggiore Hospital, Bologna, Italy.

A 35-yr-old woman is described as having atypical McCune-Albright syndrome, associated with acromegaly and hyperprolactinemia due to pituitary adenoma. The patient did not present sexual precocity, but primary amenorrhea. After transphenoidal adenomectomy, the GH plasma levels returned to normal, whereas the PRL values decreased; bromocriptine therapy normalized PRL levels and induced ovulatory menses. After 4 uneventful yr the patient developed relapse of active acromegaly that did not recover after a second neurosurgical exploration. Bromocriptine treatment maintained normal PRL levels but did not significantly reduce GH ones; the association with long-acting somatostatin analog SMS 201-995 by continuous sc pump infusion induced definitive control of GH and somatomedin-C secretion. These results suggest an additive inhibitory effect on GH secretion exerted by the two drugs.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Galland, P. Kamenicky, H. Affres, Y. Reznik, D. Pontvert, Y. Le Bouc, J. Young, and P. Chanson
McCune-Albright Syndrome and Acromegaly: Effects of Hypothalamopituitary Radiotherapy and/or Pegvisomant in Somatostatin Analog-Resistant Patients
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4957 - 4961.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. O. Akintoye, C. Chebli, S. Booher, P. Feuillan, H. Kushner, D. Leroith, N. Cherman, P. Bianco, S. Wientroub, P. G. Robey, et al.
Characterization of gsp-Mediated Growth Hormone Excess in the Context of McCune-Albright Syndrome
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5104 - 5112.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Barlier, G. Gunz, A. J. Zamora, I. Morange-Ramos, D. Figarella-Branger, H. Dufour, A. Enjalbert, and P. Jaquet
Pronostic and Therapeutic Consequences of Gs{alpha} Mutations in Somatotroph Adenomas
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1604 - 1610.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society